A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 442-447

  Secord, Angeles Alvarez ^a   Havrilesky, Laura J ^a   O'Malley, David M ^b   Bae Jump, Victoria ^c   Fleming, Nicole D ^a   Broadwater, Gloria ^d   Cohn, David E ^b   Gehrig, Paola A ^c  

^a DUKE CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Endometrial cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; SKIN DISEASE; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67651154111     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.005     Document Type: Article

References (17)

1. Ueda S.M., Kapp D.S., Cheung M.K., Shin J.Y., Osann K., Husain A., et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am. J. Obstet. Gynecol. (2008) 98
2. Smith R.S., Kapp D.S., Chen Q., and Teng N.N.H. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 767-778
3. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler L., et al. A randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 24 (2006) 36-44
4. Onda T., Yoshikawa H., Mizutani K., Mishima M., Yokota H., Nagano H., et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br. J. Cancer. 75 (1997) 1836-1841
5. Goff B.A., Goodman A., Muntz H.G., Fuller A.F., Nikrui N., and Rice L.W. Surgical stage-IV endometrial carcinoma - a study of 47 cases. Gynecol. Oncol. 52 (1994) 237-240
6. American Cancer Society. Cancer Facts and Figures 2008 (2008), Atlanta, American Cancer Society
7. Mundt A.J., McBride R., Rotmensch J., Waggoner S.E., Yamada S.D., and Connell P.P. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 1145-1153
8. Aoki Y., Kase H., Watanabe M., Sato T., Kurata H., Tanaka K., and Stage I.I.I. endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol. Oncol. 83 (2001) 1-5
9. Secord A.A., Havrilesky L.J., Bae-Jump V., Chin J., Calingaert B., Bland A., et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol. Oncol. 107 (2007) 285-291
10. Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 (2001) 4048-4053
11. Gehrig P.A., Skinner E.N., Boggess J.F., Moller K.A., Boruta D.M., Dunlap A.P., et al. Paclitaxel and carboplatin sequenced with radiotherapy in women with advanced uterine serous carcinoma: is this the optimal therapy?. J. Clin. Oncol. 22 14S (2007) 5084
12. Lupe K., Kwon J., D'Souza D., Gawlik C., Stitt L., Whiston F., et al. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 110-116
13. Fields A.L., Einstein M.H., Novetsky A.P., Gebb J., and Goldberg G.L. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 108 (2008) 201-206
14. Hryniuk W.M. Average relative dose intensity and the impact on design of clinical-trials. Semin. Oncol. 14 (1987) 65-74
15. Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Aletti G., and Podratz K.C. Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol. Oncol. 87 (2002) 112-117
16. Fleming G.F., Brurietto L., Cella D., Look K.Y., Reid G.C.H., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 2159-2166
17. Homesley H.D., Filiaci V., Gibbons S.K., Long H.J., Spirtos N.M., Morris R.T., et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol. Oncol. 108 (2008) S2